We are a global leader in oral appliances for the treatment of sleep apnoea. Clinical research, continuous innovation and instituting medical manufacturing standards have resulted in SomnoMed® becoming the market leader in oral device therapy for Obstructive Sleep Apnoea(OSA).
SomnoMed’s products are 510(k) cleared by the FDA and manufactured in accordance with ISO 13485 quality standards. More than 625,000 patients around the world have been treated with a SomnoMed device. Worn during sleep and fitted by a dental sleep specialist, SomnoMed®’s oral devices are customized to offer superior comfort and clinical effectiveness for every patient.
SomnoMed® is a company publicly traded on the Australian Stock Exchange (ASX:SOM). It was founded in 2004 in Sydney, Australia.
Every State in the United States of America, and most countries throughout the world have their own laws regulating the types of securities and other investment products which maybe offered to their residents, as well as the process for doing so. As a result, investment in some securities is not available to every interested investor. Accordingly, this information is provided for informational purposes only, and does not constitute an offer or solicitation to buy or sell SomnoMed® Limited shares in any jurisdiction where such would be prohibited.
All investments involve different degrees of risk. In making any investment you should be aware of your risk tolerance level and financial situations at all times. Furthermore, you should seek professional investment advice before making any investment decisions. Somnomed® Limited and/or its shareholders, directors, officers and/or employees make no investment recommendations in respect to any investment made in Somnomed® Limited.
Find out more about Somnomed®’s board of directors, executive team and corporate governance.